Mark Armanini

Sutro Biopharma (United States) — United States

Neuroscience · Life Sciences

39h-index17.2kcitations73works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nerve injury and regeneration(21), Neurogenesis and neuroplasticity mechanisms(14), HER2/EGFR in Cancer Research(12), Monoclonal and Polyclonal Antibodies Research(8), Lung Cancer Treatments and Mutations(7)

Publications73 total

Data from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025· 1 citedOpen Access
Figure S3 from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025Open Access
Figure S2 from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025Open Access
Figure S1 from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025Open Access
Figure S4 from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025Open Access
The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
Molecular Cancer Therapeutics·2025· 3 citedOpen Access
Abstract 1572: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors
Cancer Research·2025
Abstract 3299: Anti-FRα antibody-drug conjugate luveltamab tazevibulin for the treatment of FRα-expressing non-small cell lung cancer
Cancer Research·2025
Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
2023Open Access
Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
2023Open Access
Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
2023Open Access
Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
2023Open Access
689 ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action
Regular and Young Investigator Award Abstracts·2020Open Access
Attenuated Interferon-α Targeted to CD38 Expressing Multiple Myeloma Tumor Cells Induces Robust and Durable Anti-Tumor Responses through Direct Anti-Proliferative Activity in Addition to Indirect Recruitment and Activation of M1 Macrophages
Blood·2017· 1 cited
Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Clinical Cancer Research·2015· 26 cited
Recital and scores
Open Collections·2010Open Access
The RAV12 Monoclonal Antibody Recognizes the N-Linked Glycotope RAAG12: Expression in Human Normal and Tumor Tissues
Archives of Pathology & Laboratory Medicine·2009· 7 cited
The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues.
PubMed·2009· 8 cited
Monoclonal antibody KID24 targets human ADAM9 and is a potent inhibitor of tumor growth and metastasis in vivo
Cancer Research·2008
Antibodies generated by conditioned cell immunization technology bind to beta 5 integrin and synergize with chemotherapy and radiation to inhibit the growth of human tumor cells
Molecular Cancer Therapeutics·2007
page 1 of 4Next →

Frequent Co-authors

Heidi Phillips(32), Arnon Rosenthal(16), Kris Poulsen(8), Donna M. Stone(7), Frédéric J. de Sauvage(7), Mary Hynes(6), Christopher E. Henderson(6), Richard Vandlen(5), Audrey D. Goddard(5), Gregory L. Bennett(5), Anne Ryan(4), Laura Simmons(4), John Winslow(4), Stephen B. McMahon(4), Wei-Hsien Ho(4), Barbara Moffat(4), Charles Bakhit(4), Ingrid W. Caras(4), Isabel Fariñas(3), Natasha Shinsky(3)